FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978331495> ?p ?o ?g. }

• W1978331495 abstract "Introduction: In 1992, fibrosing colonopathy was noted in patients with cystic fibrosis (CF). High doses of pancreatic enzyme supplements were felt to be an etiologic factor. We developed an algorithm for decreasing pancreatic enzyme doses of patients who were receiving doses higher than those recommended by the CF foundation. Aims: To decrease pancreatic enzyme doses in patients with CF receiving high doses by 1) identifying the factors responsible for the presumed need for high doses, 2) identifying the successful interventions associated with the use of lower doses. Methods: We surveyed all patient charts at our CF center and determined their dose of pancreatic enzymes (lipase unitslkg/meal). All patients who were receiving more than 3000 lipase unitslkg/meal were included in the study. Charts were analyzed for reasons for excessive dosing, medications and factors responsible for decreasing enzyme dosing. A computerized program (SPSS 9.0) was used for statistical analysis. Results: Of the 176 patients followed at the CF center, 58 patients (33%) were on high doses of enzymes. Mean age at the time of intervention was 12.6 years z 4.6 SD. Prior to intervention, mean dose of enzyme supplementation was 6372 ::': 3143 SD lipase unitslkg/meal. Following intervention, the mean dose was 3414 ::': 1145 SD lipase unitslkg/meal (p less than 0.001). Dosage of enzyme was changed in 56 patients (97%). Preparation type was changed in 40 patients (69%). Interventions included change in timing of enzyme administration in 21 patients (44%), dietary changes after analysis of diet history in 30 patients (58%): addition of fiber in 6 patients (15.4%), removal of excess juice intake in 1 patient (2.1%). Dose of histamine receptor (H2) blockers were changed in 38 patients (66%); 16 were decreased, 22 increased. A stool softener was added in 17 patients (29%). Conclusions: The identification of the reason for high doses of pancreatic enzymes and the development of a systematic approach for all patients in a CF center allows for the successful intervention and the use of lower and more appropriate pancreatic enzyme replacement therapy." @default.
• W1978331495 created "2016-06-24" @default.
• W1978331495 creator A5003654348 @default.
• W1978331495 creator A5004236070 @default.
• W1978331495 creator A5046361998 @default.
• W1978331495 creator A5051071461 @default.
• W1978331495 creator A5081906787 @default.
• W1978331495 date "2000-04-01" @default.
• W1978331495 modified "2023-10-10" @default.
• W1978331495 title "Lowering doses of pancreatic enzyme supplementation in patients with cystic fibrosis" @default.
• W1978331495 doi "https://doi.org/10.1016/s0016-5085(00)82339-2" @default.
• W1978331495 hasPublicationYear "2000" @default.
• W1978331495 type Work @default.
• W1978331495 sameAs 1978331495 @default.
• W1978331495 citedByCount "0" @default.
• W1978331495 crossrefType "journal-article" @default.
• W1978331495 hasAuthorship W1978331495A5003654348 @default.
• W1978331495 hasAuthorship W1978331495A5004236070 @default.
• W1978331495 hasAuthorship W1978331495A5046361998 @default.
• W1978331495 hasAuthorship W1978331495A5051071461 @default.
• W1978331495 hasAuthorship W1978331495A5081906787 @default.
• W1978331495 hasConcept C118552586 @default.
• W1978331495 hasConcept C126322002 @default.
• W1978331495 hasConcept C181199279 @default.
• W1978331495 hasConcept C27415008 @default.
• W1978331495 hasConcept C2776737053 @default.
• W1978331495 hasConcept C2776938444 @default.
• W1978331495 hasConcept C2777288759 @default.
• W1978331495 hasConcept C2778345441 @default.
• W1978331495 hasConcept C2778764654 @default.
• W1978331495 hasConcept C2779697368 @default.
• W1978331495 hasConcept C3019860435 @default.
• W1978331495 hasConcept C55493867 @default.
• W1978331495 hasConcept C71924100 @default.
• W1978331495 hasConcept C86803240 @default.
• W1978331495 hasConcept C90924648 @default.
• W1978331495 hasConceptScore W1978331495C118552586 @default.
• W1978331495 hasConceptScore W1978331495C126322002 @default.
• W1978331495 hasConceptScore W1978331495C181199279 @default.
• W1978331495 hasConceptScore W1978331495C27415008 @default.
• W1978331495 hasConceptScore W1978331495C2776737053 @default.
• W1978331495 hasConceptScore W1978331495C2776938444 @default.
• W1978331495 hasConceptScore W1978331495C2777288759 @default.
• W1978331495 hasConceptScore W1978331495C2778345441 @default.
• W1978331495 hasConceptScore W1978331495C2778764654 @default.
• W1978331495 hasConceptScore W1978331495C2779697368 @default.
• W1978331495 hasConceptScore W1978331495C3019860435 @default.
• W1978331495 hasConceptScore W1978331495C55493867 @default.
• W1978331495 hasConceptScore W1978331495C71924100 @default.
• W1978331495 hasConceptScore W1978331495C86803240 @default.
• W1978331495 hasConceptScore W1978331495C90924648 @default.
• W1978331495 hasLocation W19783314951 @default.
• W1978331495 hasOpenAccess W1978331495 @default.
• W1978331495 hasPrimaryLocation W19783314951 @default.
• W1978331495 hasRelatedWork W1608710271 @default.
• W1978331495 hasRelatedWork W2003853489 @default.
• W1978331495 hasRelatedWork W2073422594 @default.
• W1978331495 hasRelatedWork W2122437117 @default.
• W1978331495 hasRelatedWork W2342241593 @default.
• W1978331495 hasRelatedWork W2419572499 @default.
• W1978331495 hasRelatedWork W2436709370 @default.
• W1978331495 hasRelatedWork W2474771160 @default.
• W1978331495 hasRelatedWork W2595744407 @default.
• W1978331495 hasRelatedWork W2744213233 @default.
• W1978331495 hasRelatedWork W2769038913 @default.
• W1978331495 hasRelatedWork W2891714387 @default.
• W1978331495 hasRelatedWork W2978313397 @default.
• W1978331495 hasRelatedWork W3036734543 @default.
• W1978331495 hasRelatedWork W3085465371 @default.
• W1978331495 hasRelatedWork W2695769362 @default.
• W1978331495 isParatext "false" @default.
• W1978331495 isRetracted "false" @default.
• W1978331495 magId "1978331495" @default.
• W1978331495 workType "article" @default.